PMC:7078228 / 10158-11277
Annnotations
LitCovid-PubTator
| Id | Subject | Object | Predicate | Lexical cue | tao:has_database_id |
|---|---|---|---|---|---|
| 322 | 112-120 | Species | denotes | patients | Tax:9606 |
| 323 | 135-145 | Species | denotes | SARS-CoV-2 | Tax:2697049 |
| 324 | 495-503 | Species | denotes | patients | Tax:9606 |
| 325 | 260-263 | Chemical | denotes | HCQ | MESH:D006886 |
| 326 | 505-508 | Chemical | denotes | HCQ | MESH:D006886 |
| 327 | 608-611 | Chemical | denotes | HCQ | MESH:D006886 |
| 328 | 876-879 | Chemical | denotes | HCQ | MESH:D006886 |
| 329 | 899-901 | Chemical | denotes | CQ | MESH:D002738 |
| 330 | 988-991 | Chemical | denotes | HCQ | MESH:D006886 |
| 331 | 97-111 | Disease | denotes | critically ill | MESH:D016638 |
| 332 | 121-129 | Disease | denotes | infected | MESH:D007239 |
| 333 | 347-366 | Disease | denotes | autoimmune diseases | MESH:D001327 |
| 334 | 486-494 | Disease | denotes | COVID-19 | MESH:C000657245 |
| 335 | 641-656 | Disease | denotes | CoV-2 infection | MESH:C000657245 |
| 336 | 917-925 | Disease | denotes | overdose | MESH:D062787 |
| 337 | 1098-1118 | Disease | denotes | SARS-CoV-2 infection | MESH:C000657245 |
LitCovid-PD-FMA-UBERON
| Id | Subject | Object | Predicate | Lexical cue | fma_id |
|---|---|---|---|---|---|
| T43 | 56-65 | Body_part | denotes | cytokines | http://purl.org/sig/ont/fma/fma84050 |
| T44 | 87-93 | Body_part | denotes | plasma | http://purl.org/sig/ont/fma/fma62970 |
| T45 | 163-171 | Body_part | denotes | cytokine | http://purl.org/sig/ont/fma/fma84050 |
| T46 | 416-425 | Body_part | denotes | cytokines | http://purl.org/sig/ont/fma/fma84050 |
LitCovid-PD-MONDO
| Id | Subject | Object | Predicate | Lexical cue | mondo_id |
|---|---|---|---|---|---|
| T45 | 135-143 | Disease | denotes | SARS-CoV | http://purl.obolibrary.org/obo/MONDO_0005091 |
| T46 | 347-366 | Disease | denotes | autoimmune diseases | http://purl.obolibrary.org/obo/MONDO_0007179 |
| T47 | 486-494 | Disease | denotes | COVID-19 | http://purl.obolibrary.org/obo/MONDO_0100096 |
| T48 | 636-644 | Disease | denotes | SARS-CoV | http://purl.obolibrary.org/obo/MONDO_0005091 |
| T49 | 647-656 | Disease | denotes | infection | http://purl.obolibrary.org/obo/MONDO_0005550 |
| T50 | 948-957 | Disease | denotes | poisoning | http://purl.obolibrary.org/obo/MONDO_0029000 |
| T51 | 1098-1106 | Disease | denotes | SARS-CoV | http://purl.obolibrary.org/obo/MONDO_0005091 |
| T52 | 1109-1118 | Disease | denotes | infection | http://purl.obolibrary.org/obo/MONDO_0005550 |
LitCovid-PD-CLO
| Id | Subject | Object | Predicate | Lexical cue |
|---|---|---|---|---|
| T87 | 87-93 | http://purl.obolibrary.org/obo/UBERON_0001969 | denotes | plasma |
| T88 | 250-258 | http://purl.obolibrary.org/obo/CLO_0001658 | denotes | activity |
| T89 | 267-268 | http://purl.obolibrary.org/obo/CLO_0001020 | denotes | a |
| T90 | 318-321 | http://purl.obolibrary.org/obo/CLO_0051582 | denotes | has |
| T91 | 744-747 | http://purl.obolibrary.org/obo/CLO_0051582 | denotes | has |
| T92 | 748-749 | http://purl.obolibrary.org/obo/CLO_0001020 | denotes | a |
LitCovid-PD-CHEBI
| Id | Subject | Object | Predicate | Lexical cue | chebi_id |
|---|---|---|---|---|---|
| T97 | 240-249 | Chemical | denotes | antiviral | http://purl.obolibrary.org/obo/CHEBI_22587 |
| T98 | 289-312 | Chemical | denotes | anti-inflammatory agent | http://purl.obolibrary.org/obo/CHEBI_67079 |
| T99 | 739-743 | Chemical | denotes | drug | http://purl.obolibrary.org/obo/CHEBI_23888 |
| T100 | 899-901 | Chemical | denotes | CQ | http://purl.obolibrary.org/obo/CHEBI_3638 |
| T101 | 982-984 | Chemical | denotes | SI | http://purl.obolibrary.org/obo/CHEBI_90326 |
LitCovid-PD-HP
| Id | Subject | Object | Predicate | Lexical cue | hp_id |
|---|---|---|---|---|---|
| T4 | 163-177 | Phenotype | denotes | cytokine storm | http://purl.obolibrary.org/obo/HP_0033041 |
| T5 | 347-366 | Phenotype | denotes | autoimmune diseases | http://purl.obolibrary.org/obo/HP_0002960 |
LitCovid-PD-GO-BP
| Id | Subject | Object | Predicate | Lexical cue |
|---|---|---|---|---|
| T9 | 548-569 | http://purl.obolibrary.org/obo/GO_0006954 | denotes | inflammatory response |
LitCovid-sentences
| Id | Subject | Object | Predicate | Lexical cue |
|---|---|---|---|---|
| T68 | 0-217 | Sentence | denotes | Clinical investigation found that high concentration of cytokines were detected in the plasma of critically ill patients infected with SARS-CoV-2, suggesting that cytokine storm was associated with disease severity12. |
| T69 | 218-471 | Sentence | denotes | Other than its direct antiviral activity, HCQ is a safe and successful anti-inflammatory agent that has been used extensively in autoimmune diseases and can significantly decrease the production of cytokines and, in particular, pro-inflammatory factors. |
| T70 | 472-570 | Sentence | denotes | Therefore, in COVID-19 patients, HCQ may also contribute to attenuating the inflammatory response. |
| T71 | 571-666 | Sentence | denotes | In conclusion, our results show that HCQ can efficiently inhibit SARS-CoV-2 infection in vitro. |
| T72 | 667-787 | Sentence | denotes | In combination with its anti-inflammatory function, we predict that the drug has a good potential to combat the disease. |
| T73 | 788-844 | Sentence | denotes | This possibility awaits confirmation by clinical trials. |
| T74 | 845-958 | Sentence | denotes | We need to point out, although HCQ is less toxic than CQ, prolonged and overdose usage can still cause poisoning. |
| T75 | 959-1119 | Sentence | denotes | And the relatively low SI of HCQ requires careful designing and conducting of clinical trials to achieve efficient and safe control of the SARS-CoV-2 infection. |